Lite Strategy, Inc. quarterly report, Q2 FY2022

Filing identity and business context

The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2022, covering its fiscal second quarter and six months ended December 31, 2022. This does not match the request metadata naming Lite Strategy, Inc. and 2021 Q2; verify the issuer and period before relying on this summary.

MEI is a clinical-stage cancer therapeutics company. After FDA guidance prompted MEI and partner Kyowa Kirin (KKC) to discontinue zandelisib development outside Japan, MEI said it would focus on voruciclib and ME-344. KKC continues certain zandelisib trials in Japan.

Financial results and position

Second-quarter revenue included $16.6 million from revised estimates of costs to complete zandelisib-related performance obligations being closed and $8.6 million for obligations that will not commence. The resulting quarterly profit is therefore not a clear indicator of recurring operating performance. Six-month operating cash use was $29.1 million, compared with $16.3 million a year earlier; cash and cash equivalents declined by $4.8 million over the six months.

At December 31, 2022, cash, cash equivalents and short-term U.S. government investments totaled $124.2 million, down from $153.3 million at June 30, 2022. Total liabilities were $99.2 million, including $67.4 million of deferred revenue and $13.4 million of operating lease liabilities. The filing does not report conventional borrowings. Stockholders’ equity was $48.4 million. No gross or operating margin was presented; quarterly operating income was about 27% of reported revenue, substantially affected by the revenue adjustments noted above.

Changes, outlook and key risks

• Revenue rose year over year, while R&D expense fell to $15.3 million in the quarter from $21.5 million, mainly as zandelisib studies began closing. Six-month R&D fell to $34.8 million from $41.5 million.
• MEI initiated a staggered workforce reduction, initially affecting 28 employees (about 27% of the workforce). It accrued approximately $1.2 million in termination costs, paid in January 2023.
• Management said available resources should fund obligations and operations for at least 12 months from the financial statements’ issuance, while also expecting operating losses and negative operating cash flows for the foreseeable future. MEI anticipates pursuing future capital transactions; additional funding is not assured.
• Management planned to begin a Phase 1b ME-344/bevacizumab study in relapsed colorectal cancer in the first half of calendar 2023 and anticipated key interim data from the ME-344 and voruciclib programs around year-end 2023. These are plans, not guarantees.
• Nasdaq had extended MEI’s bid-price compliance period to May 8, 2023; MEI reported it had not regained compliance by the filing date. Failure to comply could risk delisting.
• Disclosure controls were deemed ineffective due to a material weakness in controls over accounting for license-agreement revenue recognition. Management described remediation efforts but gave no assurance they would succeed.
• COVID-19-related trial enrollment, study conduct and supply disruptions remained risks. The company also noted that clinical results may not predict later outcomes and that further capital may be needed.

Investor verification priorities

1. Confirm the filing belongs to the intended issuer and reporting period; the provided text identifies MEI Pharma and December 31, 2022.
2. Review the one-time $25.2 million combined revenue recognition related to zandelisib wind-down, and assess underlying recurring revenue and cash burn.
3. Check subsequent cash use, workforce actions, and whether management’s stated 12-month liquidity runway remains supportable.
4. Track voruciclib and ME-344 trial timing, results, costs, and any Japanese zandelisib milestones or royalties.
5. Verify Nasdaq bid-price compliance status and progress in remediating the revenue-recognition control weakness.